Dr Reddy's Laboratories Ltd reports results for the quarter ended in September 30 - Earnings Summary

• Dr Reddy's Laboratories Ltd RDY.N reported quarterly adjusted earnings of ₹15.05​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of ₹17.78. The mean expectation of four analysts for the quarter was for earnings of ₹16.66 per share. Wall Street expected results to range from ₹15.26 to ₹17.75 per share.

• Revenue rose 16.5% to ₹80.38 billion from a year ago; analysts expected ₹76.47 billion.

• Dr Reddy's Laboratories Ltd's reported EPS for the quarter was ₹15.05​.

• The company reported quarterly net income of ₹12.56 billion.

• Dr Reddy's Laboratories Ltd shares had fallen by 8.1% this quarter and gained 5.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is 17.00

This summary was machine generated from LSEG data November 6 at 05:22 a.m. UTC. ​All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)